Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable oesophageal cancer: integrated analysis of individual patient data from phase III trials
British Journal of Surgery · 31.05.2025 · 112 (6)
DOI: 10.1093/bjs/znaf131 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Surgery, online erschienen am 26.06.2025. Verfasst von Jun Okui und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Esophageal Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Overall survival (OS) is the standard endpoint for oncological treatment efficacy, but requires long follow-up. The aim of this study was to evaluate pCR as a surrogate for OS in oesophageal cancer.
Methods
An integrated analysis of individual patient data (IPD) from phase III trials comparing perioperative therapies for resectable oesophageal and gastro-oesophageal junction cancer was conducted. Individual-level surrogacy between pCR and OS was assessed using Kendall’s rank correlation coefficient (τ). A τ of 0.8 was considered a threshold for a good surrogate. As no method estimating τ between an ordinal endpoint and OS has been reported, a new method was proposed using the inverse-probability-of-censoring weighted estimator adjusted for tied data.
Results
Of 22 eligible trials, 10 provided IPD for 1641 patients, including 624 who received neoadjuvant chemotherapy (NAC; 45 (7.2%) achieved pCR) and 1017 who received neoadjuvant chemoradiotherapy (NACRT; 299 (29.4%) achieved pCR). In the NAC subgroup, patients with pCR had an HR for OS of 0.12 (95% c.i. 0.05 to 0.33), the C-index was 0.54 (95% c.i. 0.52 to 0.56), and τ was 0.256. In the NACRT subgroup, the HR was 0.57 (95% c.i. 0.47 to 0.70), the C-index was 0.56 (95% c.i. 0.54 to 0.58), and τ was 0.174. Hypothetical data suggested that achieving strong surrogacy (τ of 0.8) required an HR of 0.09 (95% c.i. 0.07 to 0.11).
Conclusion
Although pCR was correlated with OS, no evidence of individual-level surrogacy with OS was demonstrated, making it inappropriate to consider pCR as a surrogate endpoint for OS in resectable oesophageal cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
- Department of Biostatistics, Keio University School of Medicine, Tokyo, Japan.
- Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
- Competence Center of Swiss Group for Clinical Cancer Research (SAKK), Switzerland.
- Faculty of Medicine, University of Basel, Basel, Switzerland.
- Department of Hematology, Oncology, and Cancer Immunology, Charité-University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany.
ORCID-Profile: Jun Okui, Kengo Nagashima, Satoru Matsuda, Magnus Nilsson, Fredrik Klevebro, Shaoyuan Zhang, Charlène van der Zijden, Bianca Mostert, Bas P L Wijnhoven, Takahiro Tsushima, Ken Kato
Zitieren
APA
Okui, J., Nagashima, K., Matsuda, S., Sato, Y., Kawakubo, H., Ruhstaller, T., Thuss-Patience, P., Nilsson, M., Klevebro, F., Tan, L., Zhang, S., Aparicio, T., Piessen, G., van der Zijden, C., Mostert, B., Wijnhoven, B. P. L., Tsushima, T., Takeuchi, H., Kato, K., & Kitagawa, Y. (2025). Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable oesophageal cancer: integrated analysis of individual patient data from phase III trials. British Journal of Surgery, 112(6). https://doi.org/10.1093/bjs/znaf131
Vancouver
Okui J, Nagashima K, Matsuda S, Sato Y, Kawakubo H, Ruhstaller T, et al. Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable oesophageal cancer: integrated analysis of individual patient data from phase III trials. British Journal of Surgery. 2025;112(6). doi:10.1093/bjs/znaf131
BibTeX
@article{Okui2025,
author = {Okui, Jun and Nagashima, Kengo and Matsuda, Satoru and Sato, Yasunori and Kawakubo, Hirofumi and Ruhstaller, Thomas and Thuss-Patience, Peter and Nilsson, Magnus and Klevebro, Fredrik and Tan, Lijie and Zhang, Shaoyuan and Aparicio, Thomas and Piessen, Guillaume and van der Zijden, Charlène and Mostert, Bianca and Wijnhoven, Bas P L and Tsushima, Takahiro and Takeuchi, Hiroya and Kato, Ken and Kitagawa, Yuko},
title = {Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable oesophageal cancer: integrated analysis of individual patient data from phase III trials},
journal = {British Journal of Surgery},
year = {2025},
volume = {112},
number = {6},
doi = {10.1093/bjs/znaf131}
}
EUVIMED